Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System. (PubMed, Mayo Clin Proc Innov Qual Outcomes) - Oct 6, 2026 - "Fewer patients used concomitant treatments with liso-cel than axi-cel (49 [21.1%] vs 1019 [33.8%]; P<.001), particularly corticosteroids, azoles, and levetiracetam. Tocilizumab use was similar (8 [3.5%] liso-cel vs 97 [3.2%] axi-cel), and intravenous immunoglobulin use was rare (<1%). Liso-cel reported a more favorable safety profile than axi-cel, with fewer reports of CRS, ICANS, cytopenia, and the need for supportive medications. Although efficacy outcomes were not analyzed, safety outcomes are consistent with previously published indirect treatment comparisons and can inform evidenced-based decision-making of clinicians."
Adverse events • Journal • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|
|
Farah Toron; Lin Wang; Magdi Elsallab; Marcela V Maus; Matthew Lunning; Maxwell Jones; Moataz Ellithi; Pearl Wang; Robert Braun
|